ArticleCell reports. Medicine2020
Pattern of Relapse and Treatment Response in WNT-Activated Medulloblastoma.
Open access · goldAbstract read
In one paragraph
Article in Cell reports. Medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 48 citations in OpenAlex.
- Paediatric therapeutic development workshop on medulloblastoma.British journal of cancer · 2026Review
- High-dose chemotherapy and craniospinal irradiation-sparing approach for WNT medulloblastoma of early childhood.Journal of neuro-oncology · 2026Article
- An integrated analysis of three medulloblastoma clinical trials refines risk-stratification approaches for reducing toxicity and improving survival.Neuro-oncology · 2026Article
- Central nervous system tumors in adolescents and young adults: A Society for Neuro-Oncology Consensus Review on diagnosis, management, and future directions.Neuro-oncology · 2025Review
- Real-life experience with a "modified-MEMMAT" regimen for relapsed medulloblastoma.Therapeutic advances in medical oncology · 2025Article
- Methylation profiling in neuropathological tumors diagnosis: a comprehensive review.Frontiers in oncology · 2025Review
- Mechanistic insights into medulloblastoma relapse.Pharmacology & therapeutics · 2024Review
- Multiomic profiling of medulloblastoma reveals subtype-specific targetable alterations at the proteome and N-glycan level.Nature communications · 2024Article
- Update on Cancer Predisposition Syndromes and Surveillance Guidelines for Childhood Brain Tumors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Review
- Drivers Underlying Metastasis and Relapse in Medulloblastoma and Targeting Strategies.Cancers · 2024Review
- Clinico-Radiological Outcomes in WNT-Subgroup Medulloblastoma.Diagnostics (Basel, Switzerland) · 2024Article
- Evolution of Systemic Therapy in Medulloblastoma Including Irradiation-Sparing Approaches.Diagnostics (Basel, Switzerland) · 2023Review
- Article
- Genetic alterations of TP53 and OTX2 indicate increased risk of relapse in WNT medulloblastomas.Acta neuropathologica · 2022Article
- Long-term outcomes and late toxicity of adult medulloblastoma treated with combined modality therapy: A contemporary single-institution experience.Neuro-oncology · 2022Article
- Machine-learning approach to predict molecular subgroups of medulloblastoma using multiparametric MRI-based tumor radiomics.The British journal of radiology · 2022Article
- New Developments in the Pathogenesis, Therapeutic Targeting, and Treatment of Pediatric Medulloblastoma.Cancers · 2022Review
- Review
- Review
- Subgroup and subtype-specific outcomes in adult medulloblastoma.Acta neuropathologica · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
61 authors at 20 institutions in 16 countries.
Liana NobreDivision of Haematology/Oncology, Department of Pediatrics, The Hospital for Sick Children, Toronto, ON, Canada.
Michal ZapotockyDepartment of Pediatric Hematology and Oncology, Second Faculty of Medicine, University Hospital Motol, Charles University, Prague, Czech Republic.
Sara KhanMonash Children's Cancer Centre, Monash University, Melbourne, VIC, Australia.
Kohei FukuokaDepartment of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan.
Adriana FonsecaDivision of Haematology/Oncology, Department of Pediatrics, The Hospital for Sick Children, Toronto, ON, Canada.
Tara McKeownDivision of Haematology/Oncology, Department of Pediatrics, The Hospital for Sick Children, Toronto, ON, Canada.
David SumerauerDepartment of Pediatric Hematology and Oncology, Second Faculty of Medicine, University Hospital Motol, Charles University, Prague, Czech Republic.
Ales VichaDepartment of Pediatric Hematology and Oncology, Second Faculty of Medicine, University Hospital Motol, Charles University, Prague, Czech Republic.
Wieslawa A GrajkowskaDepartment of Pathology, The Children's Memorial Health Institute, Warsaw, Poland.
Joanna TrubickaDepartment of Pathology, The Children's Memorial Health Institute, Warsaw, Poland.
Kay Ka Wai LiDepartment of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong.
Ho-Keung NgDepartment of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong.
Luca MassimiFondazione Policlinico A. Gemelli IRCCS, Catholic University Medical School, Rome, Italy.
Ji Yeoun LeeDepartment of Neurosurgery, Division of Pediatric Neurosurgery, Seoul National University Children's Hospital, Seoul, South Korea.
Seung-Ki KimDepartment of Neurosurgery, Division of Pediatric Neurosurgery, Seoul National University Children's Hospital, Seoul, South Korea.
Shayna ZelcerDivision of Pediatric Hematology/Oncology, Western University, London, ON, Canada.
Alexandre VasiljevicDepartment of Pathology and Molecular Medicine, Division of Anatomical Pathology, McMaster University, Hamilton, ON, Canada.
Cécile Faure-ConterDepartment of Pediatrics, Institut d'Hemato-Oncologie Pediatrique, Lyon, France.
Peter HauserSecond Department of Pediatrics, Semmelweis University, Budapest, Hungary.
Boleslaw LachDepartment of Pathology and Molecular Medicine, Division of Anatomical Pathology, McMaster University and Department of Pathology and Laboratory Medicine, Hamilton General Hospital, Hamilton, ON, Canada.
Marie-Lise van Veelen-VincentDepartment of Neurosurgery, Erasmus University Medical Center, Rotterdam, the Netherlands.
Pim J FrenchDepartment of Neurology, Erasmus University Medical Center, Rotterdam, the Netherlands.
Erwin G Van MeirDepartments of Neurosurgery, Hematology, and Medical Oncology, School of Medicine and Winship Cancer Institute, Emory University, Atlanta, GA, USA.
William A WeissDepartments of Neurological Surgery and Pediatrics, University of California, San Francisco, San Francisco, CA, USA.
Nalin GuptaDepartments of Neurological Surgery and Pediatrics, University of California, San Francisco, San Francisco, CA, USA.
Ian F PollackDepartment of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Ronald L HamiltonDepartment of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Amulya A Nageswara RaoDivision of Pediatric Hematology/Oncology, Mayo Clinic, Rochester, MN, USA.
Caterina GianniniDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Joshua B RubinDepartments of Pediatrics, Anatomy, and Neurobiology, Washington University School of Medicine, St. Louis, MO, USA.
Andrew S MooreQueensland Children's Medical Research Institute, Children's Health Queensland, Brisbane, QLD, Australia.
Lola B ChamblessDepartment of Neurological Surgery, Vanderbilt Medical Center, Nashville, TN, USA.
Rajeev VibhakarDepartment of Pediatrics, University of Colorado Denver, Aurora, CO, USA.
Young Shin RaDepartment of Neurosurgery, University of Ulsan, Asan Medical Center, Seoul, South Korea.
Maura MassiminoFondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Roger E McLendonDepartment of Pathology, Duke University, Durham, NC, USA.
Helen WheelerKolling Institute of Medical Research, The University of Sydney, Sydney, NSW, Australia.
Massimo ZolloDipartimento di Medicina Molecolare e Biotecnologie Mediche DMMBM, Università di Napoli Federico II, Naples, Italy.
Veronica FerruciDipartimento di Medicina Molecolare e Biotecnologie Mediche DMMBM, Università di Napoli Federico II, Naples, Italy.
Toshihiro KumabeDepartment of Neurosurgery, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.
Claudia C FariaDivision of Neurosurgery, Centro Hospitalar Lisboa Norte, Hospital de Santa Maria, Lisbon, Portugal.
Jaroslav SterbaDepartment of Pediatric Oncology, School of Medicine, Masaryk University, Brno, Czech Republic.
Shin JungDepartment of Neurosurgery, Chonnam National University Research Institute of Medical Sciences, Chonnam National University Hwasun Hospital and Medical School, Hwasun-gun, Chonnam, South Korea.
Enrique López-AguilarDivision of Pediatric Hematology/Oncology, Hospital Pediatría Centro Médico Nacional Century XXI, Mexico City, Mexico.
Jaume MoraDevelopmental Tumor Biology Laboratory, Hospital Sant Joan de Déu, Esplugues de Llobregat, Barcelona, Spain.
Carlos G CarlottiDepartment of Surgery and Anatomy, Faculty of Medicine of Ribeirão Preto, University of Sao Paulo, São Paulo, Brazil.
James M OlsonClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Sarah LearyCancer and Blood Disorders Center, Seattle Children's Hospital, Seattle, WA, USA.
Jason CainMonash Children's Cancer Centre, Monash University, Melbourne, VIC, Australia.
Lenka KrskovaDepartment of Pathology and Molecular Medicine, University Hospital Motol, Second Faculty of Medicine, Charles University, Prague, Czech Republic.
Josef ZamecnikDepartment of Pathology and Molecular Medicine, University Hospital Motol, Second Faculty of Medicine, Charles University, Prague, Czech Republic.
Cynthia E HawkinsDivision of Pathology, The Hospital for Sick Children, Toronto, ON, Canada.
Uri TaboriDivision of Haematology/Oncology, Department of Pediatrics, The Hospital for Sick Children, Toronto, ON, Canada.
Annie HuangDivision of Haematology/Oncology, Department of Pediatrics, The Hospital for Sick Children, Toronto, ON, Canada.
Ute BartelsDivision of Haematology/Oncology, Department of Pediatrics, The Hospital for Sick Children, Toronto, ON, Canada.
Paul A NorthcottDepartment of Developmental Neurobiology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Michael D TaylorThe Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, ON, Canada.
Stephen YipDepartment of Pathology & Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
Jordan R HansfordMonash Children's Cancer Centre, Monash University, Melbourne, VIC, Australia.
Eric BouffetDivision of Haematology/Oncology, Department of Pediatrics, The Hospital for Sick Children, Toronto, ON, Canada.
Vijay RamaswamyDivision of Haematology/Oncology, Department of Pediatrics, The Hospital for Sick Children, Toronto, ON, Canada.
Charles University · CZHospital for Sick Children · CAUniversity of Toronto · CAChildren's Memorial Health Institute · PLChinese University of Hong Kong · HKErasmus MC · NLMayo Clinic in Arizona · USRoyal Children's Hospital · AUSeoul National University Children's Hospital · KRUniversity of California, San Francisco · USUniversity of Naples Federico II · ITUniversity of Pittsburgh · USAgostino Gemelli University Polyclinic · ITAsan Medical Center · KRCentro Hospitalar Lisboa Norte · PTCentro Medico Nacional Siglo XXI · MXChildren’s Health Queensland Hospital and Health Service · AUChonnam National University Hwasun Hospital · KRDuke University · USEmory University · US
Funding
Mouse models to discover new drivers of medulloblastomaR01CA159859 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI Michael D. Taylor, WILLIAM A WEISS · 2011 to 2026
$10.4MTesting a cancer patient-specific SARS-CoV-2 vaccine in chemotherapy- and radiation-treated pediatric brain tumor mouse modelsR01CA114567 · NCI · SEATTLE CHILDREN'S HOSPITAL · PI OLSON, JAMES M · 2006 to 2023
$4.9MPrevention and treatment of lethal metastases in group 3 medulloblastomaR01NS106155 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI TAYLOR, MICHAEL D., WEISS, WILLIAM A · 2018 to 2022
$2.8MMedulloblastoma and MetastasesR01CA148699 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI TAYLOR, MICHAEL D., WEISS, WILLIAM A · 2010 to 2014
$2.4MEvaluating ADGRB3 as a tumor suppressor epigenetically silenced in WNT medulloblastomaR01CA235162 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI VAN MEIR, ERWIN G. · 2019 to 2024
$2.3MTargeting Mechanisms of Medulloblastoma FormationR01NS096236 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI VAN MEIR, ERWIN G. · 2016 to 2020
$1.9MNCI NIH HHS R01 CA114567NCI NIH HHS R01 CA148699NCI NIH HHS R01 CA159859NCI NIH HHS R01 CA235162NINDS NIH HHS R01 NS096236NINDS NIH HHS R01 NS106155
Abstract
Over the past decade, wingless-activated (WNT) medulloblastoma has been identified as a candidate for therapy de-escalation based on excellent survival; however, a paucity of relapses has precluded additional analyses of markers of relapse. To address this gap in knowledge, an international cohort of 93 molecularly confirmed WNT MB was assembled, where 5-year progression-free survival is 0.84 (95%, 0.763-0.925) with 15 relapsed individuals identified. Maintenance chemotherapy is identified as a strong predictor of relapse, with individuals receiving high doses of cyclophosphamide or ifosphamide having only one very late molecularly confirmed relapse (p = 0.032). The anatomical location of recurrence is metastatic in 12 of 15 relapses, with 8 of 12 metastatic relapses in the lateral ventricles. Maintenance chemotherapy, specifically cumulative cyclophosphamide doses, is a significant predictor of relapse across WNT MB. Future efforts to de-escalate therapy need to carefully consider not only the radiation dose but also the chemotherapy regimen and the propensity for metastatic relapses.
Indexed as
AdolescentAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCerebellar NeoplasmsChildCyclophosphamideFemaleHumansIfosfamideMaleMedulloblastomaMiddle AgedNeoplasm Recurrence, LocalProgression-Free SurvivalBiomarkers, TumorCyclophosphamideIfosfamide
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.